DLL4

BOSTON, July 17, 2026 Compass Therapeutics, Inc. announced that Phase 2/3 clinical data from its investigational DLL4 × VEGF-A...

Boston, Massachusetts | April 24, 2026 Compass Therapeutics has announced it will present topline secondary endpoint data from its...